Eli Lilly's 2026 acquisitions boost over 50 biotech venture investors
read at Endpoints ↗DealPositive
Eli Lilly announced its thirteenth acquisition of 2026, continuing a busy year of dealmaking for the drugmaker.
The transactions have involved at least fifty different venture capital firms, sending early-stage investment dollars back into the biotech startup ecosystem.
Industry observers say the wide distribution of capital could spur further innovation and attract more funding to emerging biotech companies.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Lilly’s 2026 dealmaking spreads the wealth among biotech venture investors”
read at Endpoints ↗91 words · retrieved Sep 1
comments(0)
5-min edit window · permanent after that